trending Market Intelligence /marketintelligence/en/news-insights/trending/G7Gn7dZuXIx9y9-N59uVjA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Xbrane, BioAvenir enter sales, marketing agreement for Spherotide in Israel

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Xbrane, BioAvenir enter sales, marketing agreement for Spherotide in Israel

Xbrane Biopharma AB (publ) signed a distribution agreement with BioAvenir for marketing and sales of Spherotide in Israel.

Xbrane will receive 1 million Swedish kronor as a license fee, divided into up-front and milestone payments until product launch. Both companies will share the profits from the sales of the drug in Israel, where it is expected to launch in 2020.

The drug's launch in Israel is subject to market authorization from Israel's Ministry of Health.

Spherotide is used primarily in the treatment of prostate cancer, endometriosis and uterine fibroids. For the Israeli market, it will be produced in Xbrane's production facility in Italy for resale to BioAvenir.

Xbrane estimates, based on expected price and penetration, that Spherotide has a sales potential of about 5 million Swedish kronor annually in Israel.

BioAvenir is a privately held company specializing in licensing, registering, and commercializing pharmaceuticals and special products in Israel.

As of Dec. 20, US$1 was equivalent to 9.37 Swedish kroner.